Neuropathic Pain – Part I

Please Log In or Register to continue.

Release Date: May 07, 2010
Expiration Date: May 07, 2011

Expected time to complete this activity as designed: 15 minutes

Program Overview

Dr. David Simpson reviews the spectrum of neuropathies and provides a diagnostic approach to neuropathic pain in Part I.

Target Audience

This activity is designed for physicians who have an interest in enhancing their clinical skills in chronic pain management.

Learning Objectives

Upon completion of both Part I and Part II of this activity, participants should be able to:

  • Part I
    • Describe the anatomy and physiology of neuropathic pain
    • Explain the role of cutaneous nociceptive hypersensitivity in neuropathic pain
    • Discuss neuropathic pain targets and predict nociceptive effects based on drug mechanisms
    • Compare and contrast characteristics of local versus systemic treatment options for neuropathic pain
  • Part II
    • Review current research on the mechanisms of neuropathic pain
    • Clarify assessment of symptoms, signs, and consequences of prevalent neuropathic pain conditions
    • Apply evidence-based treatments for neuropathic pain in clinical practice
    • Identify research questions that need to be addressed to optimize treatment matching for patients with neuropathic pain

General Information

This activity is eligible for credit through May 7, 2011. After this date, the activity will expire and no further credit will be awarded. There are no fees for participating in or receiving credit for this online educational activity.

Follow these steps to earn CME/CE credit:
1. Read the target audience, learning objectives, and author disclosures.
2. Complete the educational content online as designed or printed out.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score of 70% on the test and complete the Activity Evaluation to provide feedback for future programming.

Certificates may be printed immediately after successfully completing the online self-assessment post-activity and evaluation.

Faculty Biography

David M. Simpson, MD
Professor of Neurology
Director of Clinical Neurophysiology Laboratories
Director of the Neuro-AIDS Program
Mount Sinai School of Medicine
New York, New York

Dr. David Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in internal medicine at University Hospitals of Cleveland, Case Western Reserve University, and a residency in neurology at Cornell University Medical Center in New York. He completed a fellowship in clinical neurophysiology at Massachusetts General Hospital, Harvard Medical School in Boston.

Dr. Simpson is currently professor of neurology at Mount Sinai School of Medicine in New York. In addition, he is director of the clinical neurophysiology laboratories and director of the Neuro-AIDS program at Mount Sinai Hospital. Dr. Simpson is the principal investigator for many studies, including the treatment of neuropathic pain in patients with painful HIV-associated neuropathy and treatment of spasticity with botulinum toxin.

Accreditation

http://www.emergingsolutionsinpain.com/images/M_images/medicom-worldwide-black.jpgCME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CME activity are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly the following disclosures were made.

Faculty Disclosure

The presenting faculty reported the following:

Dr. David Simpson has received honoraria as a consultant from Allergan, Inc., Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Ipsen, Meda Pharmaceuticals Inc., Merz Pharma, NeurogesX, and Pfizer Inc. He has received honoraria related to speakers’ bureau activities from Eli Lilly, and GlaxoSmithKline, as well as grant support related to research activities from Pfizer, NeurogesX, and Allergan.

Planner and Provider Financial Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director and Bronwyn Boyes, PharmD, director have nothing to disclose.

Adam J. Carinci, MD was the clinical reviewer for this activity and has nothing to disclose.

Conflict of Interest Resolution

To resolve identified conflicts of interest, the educational content was fully peer reviewed by members of the MediCom Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence-based, and fair balanced.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/ participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Simpson indicated that his presentation would include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for the treatment of neuropathic pain in the United States.

Hardware/Software Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@emergingsolutionsinpain.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Purdue Pharma L.P.

©2010 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.
No portion of this material may be copied or duplicated without the expressed permission of MediCom.

Please Log In or Register to continue.